New Breakthroughs Allow Companies to Expand their Reach - Research Report on Perrigo, Auxilium, Actavis, Mylan, and Salix

NEW YORK, June 6, 2013 /PRNewswire/ --

Editor Note: For more information about this release, please scroll to bottom.

Today, Wall Street Reports announced new research reports highlighting Perrigo Company (NASDAQ: PRGO), Auxilium Pharmaceuticals, Inc. (NASDAQ: AUXL), Actavis Inc. (NYSE: ACT), Mylan, Inc. (NASDAQ: MYL), and Salix Pharmaceuticals, Ltd. (NASDAQ: SLXP). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below.

Perrigo Company Research Report

On May 29, 2013, Perrigo Company (Perrigo) announced that it has filed an Abbreviated New Drug Application (ANDA) with the U.S. Food and Drug Administration (FDA) for testosterone solution, the generic version of Axiron Topical Solution. The Company previously notified Eli Lilly, the owner of the New Drug Application and Acrux DDS PTY Ltd., owners of patents listed in FDA's Orange Book and Lilly and Acrux filed suit in the United States District Court for the Southern District of Indiana on May 24, 2013. The Company also affirmed that so far, as per its knowledge, Perrigo is the only company that has been sued at this time. Joseph C. Papa, Perrigo Chairman and CEO, stated, "This filing is another example of our long-term investment in bringing new products to market. As always, Perrigo is committed to making quality healthcare more affordable for our customers." Axiron topical solution (testosterone) is a prescription medicine used to treat adult males who have low or no testosterone. Axiron is not intended for use in women or anyone under 18 years of age. The Full Research Report on Perrigo Company - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.wsreports.com/r/full_research_report/4961_PRGO]

Auxilium Pharmaceuticals, Inc. Research Report

On May 31, 2013, Auxilium Pharmaceuticals, Inc. (Auxilium) announced that its executive management is participating in the Jefferies 2013 Healthcare Conference at the Grand Hyatt in New York City. The Company's CEO and President, Adrian Adams, will present Auxilium's overview and product pipeline at 4:00 p.m. ET on Wednesday, June 5, 2013. The Jefferies 2013 Healthcare Conference will be held from June 3 to June 6, 2013. The Full Research Report on Auxilium Pharmaceuticals, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.wsreports.com/r/full_research_report/8bad_AUXL]

Actavis Inc. Research Report

On May 29, 2013, Actavis Inc. (Actavis) launched Zoledronic Acid Actavis 4mg/5ml concentrate for solution for infusion in 14 European markets. The product was first to market in Germany, Spain, Sweden, Romania and Austria on Friday, May 17, 2013 and launched on day one immediately after the SPCs (supplementary protection certificate) expired in the UK, Ireland, Switzerland, Bulgaria, the Czech Republic, Hungary, Portugal, Poland and Slovakia. Zoledronic Acid Actavis, the generic equivalent of the Zometa brand product from Novartis, is indicated for the prevention of skeletal related events (pathological fractures, spinal compression, radiation or surgery to bone, or tumor-induced hypercalcaemia) in adult patients with advanced malignancies involving bone, and the treatment of adult patients with tumor-induced hypercalcaemia (TIH). According to IMS Health, the Zometa brand product had sales of EUR269.5 million in 2012 in Europe. The Full Research Report on Actavis Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.wsreports.com/r/full_research_report/4b90_ACT]

Mylan, Inc. Research Report

On May 29, 2013, Mylan Specialty L.P. (Mylan Specialty), the fully integrated specialty pharmaceutical business of Mylan Inc. (Mylan), announced that it is partnering with an all-star roster of baseball teams to host Allergy Awareness games at select stadiums across the country. Mylan Specialty, the marketer of EpiPen (epinephrine) Auto-Injector, will kick off the series of games with the Pittsburgh Pirates. The Allergy Awareness games will feature reserved seating areas for people with potentially life-threatening (severe) allergies to peanuts, the most common food allergen among children. "In 2012, Mylan partnered with the Pittsburgh Pirates to host the first annual Allergy Awareness game, and we are excited to expand the effort this year with events across the country," said Heather Bresch, Mylan CEO. "We are proud to partner with these teams to help families managing severe allergies attend a baseball game for what may be their first time at the ballpark. These Allergy Awareness games are just one example of our commitment to help meet the needs of people at risk for anaphylaxis." The Full Research Report on Mylan, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.wsreports.com/r/full_research_report/5c2f_MYL]

Salix Pharmaceuticals, Ltd. Research Report

On May 30, 2013, Salix Pharmaceuticals (Salix) announced that it will present at two investment conferences: (i) The Jeffries 2013 Global Healthcare Conference on Wednesday, June 5, 2013, at 1:30 p.m. ET in New York City and (ii) the Wells Fargo Healthcare Conference on Tuesday, June 18, 2013 at 1:45 p.m. ET in Boston, MA. A live audio webcast of the presentations will be available at the Company's website. The Full Research Report on Salix Pharmaceuticals, Ltd. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.wsreports.com/r/full_research_report/0af0_SLXP]

EDITOR NOTES:

1. This is not company news. We are an independent source and our views do not reflect the companies mentioned.
2. Information in this release is fact checked and produced on a best efforts basis and reviewed by a CFA. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.
3. This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.
4. If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at [email protected].
5. For any urgent concerns or inquires, please contact us at [email protected].
6. Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to [email protected] for consideration.

COMPLIANCE PROCEDURE

Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Equity News Network. An outsourced research services provider has, through Chartered Financial Analysts, only reviewed the information provided by Equity News Network in this article or report according to the Procedures outlined by Equity News Network. Equity News Network is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.

NOT FINANCIAL ADVICE

Equity News Network makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED

Equity News Network is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Equity News Network whatsoever for any direct, indirect or consequential loss arising from the use of this document. Equity News Network expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Equity News Network does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

SOURCE Wall Street Reports